A gene normally involved in the regulation of embryonic development can trigger the transition of cells into more mobile types that can spread without regard for the normal biological controls that restrict metastasis, the new study shows. …
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in progression-free survival (PFS0 for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment letrozole and palbociclib, compared to letrozole alone. …
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in progression-free survival (PFS0 for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment letrozole and palbociclib, compared to letrozole alone. “We’re essentially putting the brakes on cell proliferation and causing these tumor cells to stop growing,” said Dr. Richard Finn, associate professor of medicine at UCLA and lead author of the study…
It is estimated that the seven “high-risk” HPV types found in the nonavalent vaccine can potentially prevent over 90 percent of cervical cancers and a similarly high number of other HPV-associated cancers of the vulva, vagina, anus, penis, and some head and neck cancers. “As the healthcare providers for women who suffer from cervical and lower genital tract cancers, members of the SGO have always been advocates for the primary prevention of cervical and other HPV-related cancers,” said SGO President Richard R…
And once the sleep was lost, there was no getting its positive effect back by allowing extra rest later. In “Recovery Sleep Does Not Mitigate the Effects of Prior Sleep Loss on Paclitaxel-Induced Mechanical Hypersensitivity in Sprague-Dawley Rats,” a preclinical study published in Biological Research for Nursing, restricted sleep among rats led to worse reactions to PAC, associated with painful, debilitating peripheral neuropathy of the hands and feet that may persist long after therapy is completed. According to the study, “How poor sleep sets the stage for adverse outcomes among people diagnosed with cancer is not entirely understood…
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in PFS for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment, letrozole, and palbociclib compared to letrozole alone. “We’re essentially putting the brakes on cell proliferation and causing these tumor cells to stop growing,” said Dr. …
The study, “Volumetric Breast Density Improves Breast Cancer Risk Prediction,” was presented during the 2014 San Antonio Breast Cancer Symposium. “There is increasing interest in implementing personalized breast cancer screening strategies instead of guidelines based on a woman’s age. However, most risk models do not include breast density, which is an important indicator of a woman’s breast cancer risk,” said Jennifer Harvey, MD, professor of radiology at the UVA School of Medicine…
“We found that adding either carboplatin or bevacizumab to standard preoperative chemotherapy increased pathologic complete response rates for women with basal-like cancers — that is, it increased the proportion of women who had no residual cancer detected at surgery. At the same time, we found that while carboplatin had a similar effect in the smaller group of triple-negative patients with nonbasal-like cancers, adding bevacizumab actually decreased response rates for women with nonbasal-like cancers,” says William M. Sikov, MD, associate chief of clinical research with the Program in Women’s Oncology at Women & Infants and associate professor of medicine at The Warren Alpert Medical School of Brown University…
“The p53 protein is necessary for tumor suppression,” said Xinbin Chen, professor at the UC Davis Schools of Medicine and Veterinary Medicine. “When Rbm38 suppresses p53, organisms develop tumors. Knocking out Rbm38 increases p53, which we thought might be a good thing. But too much p53 suppresses cell-cycle progression, causing cell death, premature aging and even cancer.” The relationship between p53 and Rbm38 can best be described as a loop: p53 regulates Rbm38 expression, while Rbm38 suppresses p53. …
The discovery provides possibility for both antiviral treatment and vaccine of type 1 Diabetes, according to a press release from The University of Oslo. Type 1 Diabetes affects young people and children. Unlike type 2, type 1 cannot be treated by diet changes and exercise Insulin is needed. Only 29 % of the patients reach the recommended goals for treatment to prevent disabling late diabetes complications. …